Cell Signaling Technology Logo - Extra Large
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CTLA-4 (Ipilimumab Biosimilar) Human Monoclonal Antibody #57924

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Human IgG1 kappa
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Description

    CTLA-4 (Ipilimumab Biosimilar) Human mAb is a biosimilar antibody for Ipilimumab. Ipilimumab is a therapeutic human monoclonal antibody directed against CTLA-4, an immune checkpoint protein.
    Endotoxin <0.1 EU/μg of antibody

    Product Usage Information

    This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user.

    Formulation

    Supplied in 1X PBS, BSA and Azide Free

    Storage

    Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.

    Specificity / Sensitivity

    CTLA-4 (Ipilimumab Biosimilar) Human Monoclonal Antibody was confirmed to bind to its intended target protein CTLA-4 using flow cytometry.

    Species Reactivity:

    Human

    Source / Purification

    CTLA-4 (Ipilimumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Ipilimumab is an antibody directed against the extracellular region of human CTLA-4.

    Background

    Cytotoxic T-lymphocyte protein 4 (CTLA-4, CD152) is an Ig superfamily member that negatively regulates early T cell activation (1-4). The CTLA-4 protein is primarily expressed on T cells, including CD8+ cytotoxic T cells, CD4+ helper T cells, and CD4+/FoxP3+ regulatory T cells (1,2). CTLA-4 protein competes with CD28 for B7.1 (CD80) and B7.2 (CD86) binding at the cell surface, which results in the downregulation of T cell activity (5). The activation of SHP-2 and PP2A downstream of CTLA-4 attenuates TCR signaling (6). Research studies indicate that CTLA4 knockout mice display lymphoproliferative disorders leading to early death, confirming the role of CTLA-4 as a negative regulator of T cells (7). Mutations in the corresponding CTLA4 gene are associated with multiple disorders, including insulin-dependent diabetes mellitus, Graves' disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, and type V autoimmune lymphoproliferative syndrome (8,9). Additional studies demonstrate that CTLA-4 blockade is an effective strategy for tumor immunotherapy (10-12).

    Alternate Names

    activation-inducible lymphocyte immunomediatory molecule; AILIM; ALPS5; CD; CD152; CD278; celiac disease 3; CELIAC3; CTLA-4; CTLA4; cytotoxic T lymphocyte associated antigen 4 short spliced form; cytotoxic T-lymphocyte associated protein 4; Cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated serine esterase-4; GRD4; GSE; ICOS; IDDM12; inducible costimulator; inducible T-cell co-stimulator; inducible T-cell costimulator; insulin-dependent diabetes mellitus 12; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; MGC39850

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.